Ads
related to: Acute Myeloid Leukemia and Bluebird Bio- Safety
Learn More About Well Characterized
Safety Profile.
- Dosing & Monitoring
Twice Daily
Oral Dosing.
- Mechanism of Action
Inhibits Mutant IDHI and
Restores Myeloblast Differentiation
- Access & Resources
Support is Available for
You and Your Patients.
- Safety
Search results
Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?
Motley Fool via Yahoo Finance· 5 months agoDespite the Food and Drug Administration (FDA) approving its sickle cell disease (SCD) gene therapy...
2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal
Zacks via Yahoo Finance· 8 months ago2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its...
FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another
Benzinga via Yahoo Finance· 2 years agoThe FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:...
Regeneron to acquire 2seventy’s cell therapy pipeline
BioPharma Dive via Yahoo Finance· 4 months agoAbout 150 of the smaller company's employees will also transition to Regeneron, which is setting up...
US FDA approves two gene therapies for sickle cell disease
Reuters via Yahoo News· 6 months ago(Reuters) -The U.S. Food and Drug Administration (FDA) on Friday approved two gene therapies for...
Is Beam Therapeutics Stock a Buy Now?
Motley Fool· 6 months agoWhen it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a...
FDA approves first use of CRISPR gene editing to treat sickle cell disease
The Hill via Yahoo News· 6 months agoThe Food and Drug Administration (FDA) on Friday approved a new therapy for treating sickle cell...
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
Motley Fool· 7 months agoBiotech stocks, especially those that don't have a medicine on the market yet, tend to be among the...
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
Motley Fool· 8 months agoOf course, it's complicated to figure out which are going to soar and which will languish, so it...
Beam Therapeutics Stock: Bear vs. Bull
Motley Fool· 7 months agoBefore taking the plunge into a pre-revenue gene-editing stock like Beam Therapeutics (NASDAQ: BEAM), which is probably years away from making any money,...
Ads
related to: Acute Myeloid Leukemia and Bluebird Bio
